Format

Send to

Choose Destination
Am J Cardiol. 2015 Jul 15;116(2):264-9. doi: 10.1016/j.amjcard.2015.03.061. Epub 2015 Apr 18.

Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial).

Author information

1
Herbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York. Electronic address: pg2336@columbia.edu.
2
Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
3
Herbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.
4
Baylor Healthcare System, Plano, Texas.
5
Mayo Clinic, Rochester, Minnesota.
6
Cardiopulmonary Research Science and Technology Institute (CRSTI), Plano, Texas.
7
Cardiopulmonary Research Science and Technology Institute (CRSTI), Plano, Texas; Baylor Scott and White Health, Plano, Texas.

Abstract

Transcatheter aortic valve replacement (TAVR) is an effective treatment for severe symptomatic aortic stenosis (AS) in patients who are inoperable or at high risk for surgery. However, the intermediate- to long-term mortality is high, emphasizing the importance of patient selection. We, therefore, sought to evaluate the prognostic value of frailty in older recipients of TAVR, hypothesizing that frail patients would experience a higher mortality rate and a higher likelihood of poor outcome 1 year after TAVR. This substudy of the Placement of Aortic Transcatheter Valves trial was conducted at 3 high-enrolling sites where frailty was assessed systematically before TAVR. In total, 244 patients received TAVR at the participating sites. Frailty was assessed using a composite of 4 markers (serum albumin, dominant handgrip strength, gait speed, and Katz activity of daily living survey), which were combined into a frailty score. The cohort was dichotomized at median frailty score. Outcomes measures were the time to death from any cause for >1 year of follow-up and poor outcome at 1 year. Poor outcome was defined as (1) death, (2) Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) score <60, or (3) decrease of ≥10 points in the KCCQ-OS score from baseline to 1 year. At 1 year, the Kaplan-Meier-estimated all-cause mortality rate was 32.7% in the frail group and 15.9% in the nonfrail group (log-rank p = 0.004). At 1 year, poor outcome occurred in 50.0% of the frail group and 31.5% of the nonfrail group (p = 0.02). In conclusion, frailty was associated with increased mortality and a higher rate of poor outcome 1 year after TAVR.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00530894.

PMID:
25963221
PMCID:
PMC4475494
DOI:
10.1016/j.amjcard.2015.03.061
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center